G Gifford1, J Sim, A Horne, D Ma. 1. Department of Haematology and Bone Marrow Transplantation, St Vincent's Hospital, Sydney, New South Wales, Australia.
Abstract
BACKGROUND: Survival after allogeneic haemopoietic stem cell transplantation (allo-HSCT) has improved because of advancements in allo-HSCT. Allo-HSCT has been performed in Australia since the late 1970s. However, there are few published data about health problems of allo-HSCT survivors in Australia. AIMS: Identify health issues in long-term survivors of allo-HSCT in an Australian centre to manage better and prevent long-term complications. METHODS: The health records of all patients of allo-HSCT in a single centre from January 2000 to December 2007 and survived beyond 2 years were assessed. RESULTS: Ninety-nine of the 200 allo-HSCT patients survived beyond 2 years, and the median time from allo-HSCT was 74 months. Twenty-eight per cent died at a median of 37 months after allo-HSCT because of relapsed malignancy (12%), stroke (1%), infection (3%), chronic graft versus host disease (9%), secondary malignancy (2%) and unknown cause (1%). Ninety-one per cent reported one or more chronic health conditions. Health issues were chronic graft versus host disease (70%); respiratory (66%), ophthalmic (40%), bone (33%), and renal (26%) problems; and malignancies (14% skin, 3% solid organ). Seventy-nine per cent resumed vocation at full or reduced capacity 2 years after allo-HSCT. Clinicians identified 40% with quality of life (QOL) issues, but survivors' self-reported QOL was comparable with the general Australian population. CONCLUSION: This study shows that allo-HSCT patients are living with high burdens of chronic diseases that warrant lifelong surveillance and engagement with healthcare. Structured, multi-disciplinary care as recommended by published guidelines for allo-HSCT survivors may reduce long-term effects and improve their outcomes.
BACKGROUND: Survival after allogeneic haemopoietic stem cell transplantation (allo-HSCT) has improved because of advancements in allo-HSCT. Allo-HSCT has been performed in Australia since the late 1970s. However, there are few published data about health problems of allo-HSCT survivors in Australia. AIMS: Identify health issues in long-term survivors of allo-HSCT in an Australian centre to manage better and prevent long-term complications. METHODS: The health records of all patients of allo-HSCT in a single centre from January 2000 to December 2007 and survived beyond 2 years were assessed. RESULTS: Ninety-nine of the 200 allo-HSCT patients survived beyond 2 years, and the median time from allo-HSCT was 74 months. Twenty-eight per cent died at a median of 37 months after allo-HSCT because of relapsed malignancy (12%), stroke (1%), infection (3%), chronic graft versus host disease (9%), secondary malignancy (2%) and unknown cause (1%). Ninety-one per cent reported one or more chronic health conditions. Health issues were chronic graft versus host disease (70%); respiratory (66%), ophthalmic (40%), bone (33%), and renal (26%) problems; and malignancies (14% skin, 3% solid organ). Seventy-nine per cent resumed vocation at full or reduced capacity 2 years after allo-HSCT. Clinicians identified 40% with quality of life (QOL) issues, but survivors' self-reported QOL was comparable with the general Australian population. CONCLUSION: This study shows that allo-HSCT patients are living with high burdens of chronic diseases that warrant lifelong surveillance and engagement with healthcare. Structured, multi-disciplinary care as recommended by published guidelines for allo-HSCT survivors may reduce long-term effects and improve their outcomes.
Authors: Lindsay M Morton; Wael Saber; K Scott Baker; A John Barrett; Smita Bhatia; Eric A Engels; Shahinaz M Gadalla; David E Kleiner; Steven Pavletic; Linda J Burns Journal: Biol Blood Marrow Transplant Date: 2016-09-12 Impact factor: 5.742
Authors: Christine N Duncan; Navneet S Majhail; Ruta Brazauskas; Zhiwei Wang; Jean-Yves Cahn; Haydar A Frangoul; Robert J Hayashi; Jack W Hsu; Rammurti T Kamble; Kimberly A Kasow; Nandita Khera; Hillard M Lazarus; Alison W Loren; David I Marks; Richard T Maziarz; Paulette Mehta; Kasiani C Myers; Maxim Norkin; Joseph A Pidala; David L Porter; Vijay Reddy; Wael Saber; Bipin N Savani; Harry C Schouten; Amir Steinberg; Donna A Wall; Anne B Warwick; William A Wood; Lolie C Yu; David A Jacobsohn; Mohamed L Sorror Journal: Biol Blood Marrow Transplant Date: 2014-10-12 Impact factor: 5.742
Authors: Jennifer Smith; Christine Poon; Nicole Gilroy; Masura Kabir; Lisa Brice; Gemma Dyer; Megan Hogg; Matthew Greenwood; John Moore; Mark Hertzberg; Louisa Brown; Jeff Tan; Gillian Huang; John Kwan; Stephen Larsen; Christopher Ward; Ian Kerridge Journal: Support Care Cancer Date: 2016-09-02 Impact factor: 3.603
Authors: Margaret Bevans; Areej El-Jawahri; D Kathryn Tierney; Lori Wiener; William A Wood; Flora Hoodin; Erin E Kent; Paul B Jacobsen; Stephanie J Lee; Matthew M Hsieh; Ellen M Denzen; Karen L Syrjala Journal: Biol Blood Marrow Transplant Date: 2016-09-19 Impact factor: 5.742
Authors: Nirali N Shah; Alexandra F Freeman; Helen Su; Kristen Cole; Mark Parta; Niki M Moutsopoulos; Safa Baris; Elif Karakoc-Aydiner; Thomas E Hughes; Heidi H Kong; Steve M Holland; Dennis D Hickstein Journal: Biol Blood Marrow Transplant Date: 2017-03-10 Impact factor: 5.742
Authors: Jacqueline P Williams; Laura Calvi; Joe V Chakkalakal; Jacob N Finkelstein; M Kerry O'Banion; Edward Puzas Journal: Radiat Res Date: 2016-06-22 Impact factor: 2.841